Given the significant changes in T cell abundance by Prmt3-KO and PRMT3 inhibition, we then examined whether the effects of Prmt3-KO and PRMT3 inhibition on tumor progression were mediated by CD8+ or CD4+ T cells. This evidence concerns the gene CD4 and neoplasm.